vs

Side-by-side financial comparison of Ballard Power Systems Inc. (BLDP) and SUTRO BIOPHARMA, INC. (STRO). Click either name above to swap in a different company.

Ballard Power Systems Inc. is the larger business by last-quarter revenue ($17.7M vs $11.6M, roughly 1.5× SUTRO BIOPHARMA, INC.).

Ballard Power Systems Inc. is a developer and manufacturer of proton exchange membrane (PEM) fuel cell products for markets such as heavy-duty motive, portable power, material handling as well as engineering services. Ballard has designed and shipped over 400 MW of fuel cell products to date.

Sutro Biopharma, Inc. is a publicly traded biotechnology company headquartered in South San Francisco, California focused on clinical-stage drug discovery, development and manufacturing. Using a proprietary cell-free protein synthesis platform, Sutro is working on oncology therapeutics using protein engineering and rational design. Founded in 2003 under the name Fundamental Applied Biology, the company name changed to Sutro Biopharma in 2009. William Newell, CEO as of 2024, joined Sutro in Ja...

BLDP vs STRO — Head-to-Head

Bigger by revenue
BLDP
BLDP
1.5× larger
BLDP
$17.7M
$11.6M
STRO

Income Statement — Q3 FY2025 vs Q4 FY2025

Metric
BLDP
BLDP
STRO
STRO
Revenue
$17.7M
$11.6M
Net Profit
$176.5M
Gross Margin
Operating Margin
Net Margin
994.4%
Revenue YoY
-21.4%
Net Profit YoY
35.4%
EPS (diluted)

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
BLDP
BLDP
STRO
STRO
Q4 25
$11.6M
Q3 25
$17.7M
$9.7M
Q2 25
$63.7M
Q1 25
$17.4M
Q4 24
$14.8M
Q3 24
$-12.3M
$8.5M
Q2 24
$25.7M
Q1 24
$13.0M
Net Profit
BLDP
BLDP
STRO
STRO
Q4 25
Q3 25
$176.5M
$-56.9M
Q2 25
$-11.5M
Q1 25
$-76.0M
Q4 24
$-72.4M
Q3 24
$-48.8M
Q2 24
$-48.0M
Q1 24
$-58.2M
Gross Margin
BLDP
BLDP
STRO
STRO
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
156.5%
Q2 24
Q1 24
Operating Margin
BLDP
BLDP
STRO
STRO
Q4 25
Q3 25
-499.9%
Q2 25
-5.2%
Q1 25
-393.8%
Q4 24
-440.7%
Q3 24
-797.2%
Q2 24
-189.4%
Q1 24
-435.0%
Net Margin
BLDP
BLDP
STRO
STRO
Q4 25
Q3 25
994.4%
-586.6%
Q2 25
-18.0%
Q1 25
-436.6%
Q4 24
-489.2%
Q3 24
-572.6%
Q2 24
-186.8%
Q1 24
-447.5%
EPS (diluted)
BLDP
BLDP
STRO
STRO
Q4 25
Q3 25
$-0.67
Q2 25
$-0.14
Q1 25
$-0.91
Q4 24
$-27.63
Q3 24
$-0.59
Q2 24
$-0.59
Q1 24
$-0.59

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
BLDP
BLDP
STRO
STRO
Cash + ST InvestmentsLiquidity on hand
$141.4M
Total DebtLower is stronger
Stockholders' EquityBook value
$-132.5M
Total Assets
$173.8M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
BLDP
BLDP
STRO
STRO
Q4 25
$141.4M
Q3 25
$167.6M
Q2 25
$205.1M
Q1 25
$249.0M
Q4 24
$316.9M
Q3 24
$388.3M
Q2 24
$375.6M
Q1 24
$267.6M
Stockholders' Equity
BLDP
BLDP
STRO
STRO
Q4 25
$-132.5M
Q3 25
$-87.3M
Q2 25
$-32.1M
Q1 25
$-25.8M
Q4 24
$44.6M
Q3 24
$111.2M
Q2 24
$152.2M
Q1 24
$98.0M
Total Assets
BLDP
BLDP
STRO
STRO
Q4 25
$173.8M
Q3 25
$209.7M
Q2 25
$262.4M
Q1 25
$321.4M
Q4 24
$387.2M
Q3 24
$451.8M
Q2 24
$489.0M
Q1 24
$403.4M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
BLDP
BLDP
STRO
STRO
Operating Cash FlowLast quarter
$5.7M
$-177.2M
Free Cash FlowOCF − Capex
FCF MarginFCF / Revenue
Capex IntensityCapex / Revenue
Cash ConversionOCF / Net Profit
0.03×
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
BLDP
BLDP
STRO
STRO
Q4 25
$-177.2M
Q3 25
$5.7M
$-38.2M
Q2 25
$-44.7M
Q1 25
$-67.9M
Q4 24
$-71.7M
Q3 24
$-6.6M
$-64.5M
Q2 24
$9.5M
Q1 24
$-64.7M
Cash Conversion
BLDP
BLDP
STRO
STRO
Q4 25
Q3 25
0.03×
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons